AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.

Ludovic Helfgott, Vice President, Cardiovascular and Metabolic Diseases, said: “With the breadth of our scientific updates at AHA 2017, we are at the forefront of the clinical debate, exploring the often unseen but vital connections between cardiovascular, renal and metabolic diseases. This approach embodies our commitment to improving outcomes for patients while reducing long-term morbidity and mortality.”

Key among the data being presented are two late-breaking presentations selected by the AHA: the China-based DACAB study (Efficacy of Different Antiplatelet Therapy Strategy after Coronary Artery Bypass Grafting); and the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial, plus data for potential new CVMD medicines.

  • The DACAB study compares the use of Brilinta (ticagrelor) plus aspirin versus aspirin alone, and Brilinta alone following elective coronary artery bypass graft surgery (CABG), to assess patency of the grafts. (Session LBS.01)
  • A new analysis of the EXSCEL clinical trial, the largest and most inclusive CV outcomes trial of any glucagon-like peptide-1 receptor agonist (GLP-1 RA), with more than 14,500 patients at 687 trial sites across 35 countries, aims to further demonstrate the effect of Bydureon (exenatide) once-weekly on CV morbidity and mortality in patients with type-2 diabetes. This new analysis adds to results presented at the recent annual meeting of the European Association for the Study of Diabetes (EASD), and published simultaneously in the New England Journal of Medicine. (Session LBS.04)
  • Presentations at AHA also include early stage data for potential new medicines, as monotherapy and in combinations, in areas including cardiac regeneration, chronic kidney disease, acute coronary syndromes, and chronic heart failure. These include Phase IIa data of MEDI6012, a recombinant human lecithin-cholesterol acyltransferase (LCAT) being evaluated for the treatment of coronary artery disease (Session LB.APS.06 – S2107) and CHF, as well as data from AZD5718 our 5-lipoxygenase activating protein (FLAP), a potential treatment for ACS (Session IN.APS.02 – S4093).


For the full listing of AstraZeneca/MedImmune Presentations at AHA 2017, please visit!/4412/.

About AstraZeneca in Cardiovascular, Renal & Metabolic Diseases (CVMD)

Cardiovascular, renal and metabolic diseases together form one of AstraZeneca’s main therapy areas and platforms for future growth. By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVMDs and even regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and CVMD health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit and follow us on Twitter @AstraZeneca.


Media Relations





Esra Erkal-Paler


+44 203 749 5638

Karen Birmingham


+44 203 749 5634

Rob Skelding


+44 203 749 5821

Matt Kent


+44 203 749 5906

Gonzalo Viña


+44 203 749 5916

Jacob Lund


+46 8 553 260 20

Michele Meixell


+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler


+44 203 749 5797

Mitchell Chan


+1 240 477 3771

Christer Gruvris

Diabetes; Autoimmunity, Neuroscience & Infection

+44 203 749 5711

Nick Stone

Respiratory, Brilinta

+44 203 749 5716

US Toll-Free


+1 866 381 7277


  • Corporate and financial